Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joel D Allen

Showing results (51-60 of 91) with videos related to

Pageof 10
Sort By:
NPJ Vaccines|July 12, 2024
Priming antibody responses to the fusion peptide in rhesus macaquesChristopher A Cottrell, Payal P Pratap, Kimberly M Cirelli, et al.
Biorxiv : the Preprint Server for Biology|January 27, 2021
Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccineYasunori Watanabe, Luiza Mendonça, Elizabeth R Allen, et al.
Medrxiv : the Preprint Server for Health Sciences|November 25, 2020
Serological responses to SARS-CoV-2 following non-hospitalised infection: clinical and ethnodemographic features associated with the magnitude of the antibody responseAdrian M Shields, Sian E Faustini, Marisol Perez-Toledo, et al.
BMJ Open Respiratory Research|September 25, 2021
Serological responses to SARS-CoV-2 following non-hospitalised infection: clinical and ethnodemographic features associated with the magnitude of the antibody responseAdrian M Shields, Sian E Faustini, Marisol Perez-Toledo, et al.
Biorxiv : the Preprint Server for Biology|June 29, 2026
Translating Innovation to Clinic: End-to-End Bioprocess Development and cGMP Manufacturing of N332-GT5 HIV Vaccine Candidate for First-in-Human Trials HVTN144Sammaiah Pallerla, Shaunak Uplekar, Ferenc Boldog, et al.
NPJ Vaccines|February 10, 2021
Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticlesPhilip J M Brouwer, Aleksandar Antanasijevic, Marlon de Gast, et al.
Medrxiv : the Preprint Server for Health Sciences|June 25, 2020
Serology confirms SARS-CoV-2 infection in PCR-negative children presenting with Paediatric Inflammatory Multi-System SyndromeMarisol Perez-Toledo, Sian E Faustini, Sian E Jossi, et al.
Blood|August 23, 2021
Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behaviorGiorgia Chiodin, Joel D Allen, Dean J Bryant, et al.
Plos Pathogens|August 12, 2020
Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogensAleksandar Antanasijevic, George Ueda, Philip J M Brouwer, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2023
Focusing antibody responses to the fusion peptide in rhesus macaquesChristopher A Cottrell, Payal P Pratap, Kimberly M Cirelli, et al.
Pageof 10

Showing results (51-60 of 91) with videos related to

Sort By:
Pageof 10
NPJ Vaccines|July 12, 2024
Priming antibody responses to the fusion peptide in rhesus macaquesChristopher A Cottrell, Payal P Pratap, Kimberly M Cirelli, et al.
Biorxiv : the Preprint Server for Biology|January 27, 2021
Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccineYasunori Watanabe, Luiza Mendonça, Elizabeth R Allen, et al.
Medrxiv : the Preprint Server for Health Sciences|November 25, 2020
Serological responses to SARS-CoV-2 following non-hospitalised infection: clinical and ethnodemographic features associated with the magnitude of the antibody responseAdrian M Shields, Sian E Faustini, Marisol Perez-Toledo, et al.
BMJ Open Respiratory Research|September 25, 2021
Serological responses to SARS-CoV-2 following non-hospitalised infection: clinical and ethnodemographic features associated with the magnitude of the antibody responseAdrian M Shields, Sian E Faustini, Marisol Perez-Toledo, et al.
Biorxiv : the Preprint Server for Biology|June 29, 2026
Translating Innovation to Clinic: End-to-End Bioprocess Development and cGMP Manufacturing of N332-GT5 HIV Vaccine Candidate for First-in-Human Trials HVTN144Sammaiah Pallerla, Shaunak Uplekar, Ferenc Boldog, et al.
NPJ Vaccines|February 10, 2021
Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticlesPhilip J M Brouwer, Aleksandar Antanasijevic, Marlon de Gast, et al.
Medrxiv : the Preprint Server for Health Sciences|June 25, 2020
Serology confirms SARS-CoV-2 infection in PCR-negative children presenting with Paediatric Inflammatory Multi-System SyndromeMarisol Perez-Toledo, Sian E Faustini, Sian E Jossi, et al.
Blood|August 23, 2021
Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behaviorGiorgia Chiodin, Joel D Allen, Dean J Bryant, et al.
Plos Pathogens|August 12, 2020
Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogensAleksandar Antanasijevic, George Ueda, Philip J M Brouwer, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2023
Focusing antibody responses to the fusion peptide in rhesus macaquesChristopher A Cottrell, Payal P Pratap, Kimberly M Cirelli, et al.
Pageof 10